SERO Serologicals (MM)

Serologicals Corporation (NASDAQ: SERO) announced today that it has been awarded an Editor's Choice Technology & Business award from Start magazine. Serologicals President and CEO David A. Dodd will accept the award at the 8th Annual Technology & Business Awards ceremony on August 11 in Chicago. Start will award four manufacturers the Editor's Choice Technology & Business award. The winners were selected for their commitment and understanding of how technology can help them improve and enhance their company. In conjunction with the award ceremony, Dodd is scheduled to speak at Start magazine's manufacturing conference on August 11. More than 50 key manufacturing executives will be in attendance for Dodd's presentation titled "A CEO's Guide to Seamless Integration of Acquisitions." Start magazine ranked Dodd as one of its 21 "CEO Visionaries" in the April 2005 issue. Other recent awards Dodd has received include the 2004 Georgia Biomedical Partnership Biomedical Industry Growth Award for his efforts in promoting Georgia's life sciences industry. Dodd also received the 2005 Oglethorpe Award from the Atlanta Chapter of the British American Business Group, in recognition of his ongoing leadership in fostering business relationships between the U.S. and the United Kingdom. Start magazine focuses on the greater business issues that can be solved for manufacturing executives. Top executives have come to rely on Start for sound technological advice coupled with solid coverage of the financial, political, and management. Since its inception in 1997, Start has focused on reaching the C-level suite. Today, 85,000 top manufacturing executives -- CEOs, presidents, CFOs, CIOs, CTOs, COOs, vice presidents, and other executives -- have come to rely on Start's keen editorial each month. Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA., is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA. For more information, please visit our website: www.serologicals.com.